Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Tight Packaging Shuts Down Tumor Suppressor Genes

By LabMedica International staff writers
Posted on 16 Dec 2008
A publication stressed the importance of considering the three dimensional structure of DNA and its associated chromatin packaging when assessing the link between tumor suppressor gene expression and cancer development.

Investigators at Johns Hopkins University (Baltimore, MD, USA) examined the relationship between structure and expression of the gene GATA-4 in embryonic cells and in mature colon cancer cells. More...
They concentrated on two factors that modulated expression of the gene: chromatin packaging and degree of methylation.

They reported in the December 2, 2008, issue of the journal PLoS Biology that chromatin packaging was characterized by the interaction of GATA-4 DNA with Polycomb group proteins (PcG). Polycomb-group proteins are a family of proteins first discovered in fruit flies that can remodel chromatin such that transcription factors cannot bind to promoter sequences in DNA. In humans, abnormal levels of PcG proteins correlate with the severity and invasiveness of several cancer types.

In embryonic cells, GATA-4 was packaged by PcG proteins, in a low expression state, and had no DNA methylation. When the gene received signals for cells to mature, the PcG loops loosened and the gene became highly expressed. However, when the same gene was abnormally DNA methylated, as is the case in adult, mature colon cancer cells, the PcG packaging loops were tighter and there was no gene expression. Treatment of the cancer cells with drugs designed to de-methylate DNA caused the PcG the loops to loosen somewhat, back to the state of an embryonic cell, and some gene expression was restored.

"We think the polycomb proteins combine with abnormal DNA methylation of genes to deactivate tumor suppressor genes and lock cancer cells in a primitive state,” explained senior author Dr. Stephen B. Baylin, professor of oncology at Johns Hopkins University. "These tight loops touch and interact with many gene sites folding it into a structure that shuts off tumor suppressor genes. Demethylating agents, drugs that target and remove abnormal DNA methylation from genes, have been introduced as potential new cancer therapies. For these therapies to be fully effective, researchers may also need to look for agents that disrupt PcG loops.”

Related Links:

Johns Hopkins University


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.